Sign in

NCT05759377Completed

V-A ECMO AUTO Mode Registry

Abiomed Impella V-A ECMO AUTO Mode - Observational Study

Source: ClinicalTrials.gov · Last updated 3 Jul 2025

Brief summary (registry, in English)

Abiomed Impella V-A ECMO AUTO Mode - Observational Study

Status (registry)
Completed
Study type
Observational
Enrollment
46 (actual)
First submitted
22 Feb 2023
Start date
11 Oct 2023
Primary completion date
3 Jun 2025
Lead sponsor
Abiomed Inc.
NCT number
NCT05759377

What you commit to

  • Study type: Observational
  • Participants enrolled: 46
  • From 11 Oct 2023 to the primary completion date, 3 Jun 2025
  • 6 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Treatment with other than VA ECMO setup
  • Treatment with Impella CP® heart pump only

Age

  • Age \< 18 years

Who the study is looking for

  • Patients with ongoing or planned ECpella therapy

Age in the registry: 18 years to - · Sex: All

Full criteria on ClinicalTrials.gov

Sites (6)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Uniklinik RWTH Aachen
Coordinator of this site? Confirm its status
AachenGermanyUnknown status
HDZ NRW
Coordinator of this site? Confirm its status
Bad OeynhausenGermanyUnknown status
Herzzentrum Dresden GmbH
Coordinator of this site? Confirm its status
DresdenGermanyUnknown status
Universitäres Herz- und Gefäßzentrum Hamburg
Coordinator of this site? Confirm its status
HamburgGermanyUnknown status
UKGM Universtitätsklinikum Marburg
Coordinator of this site? Confirm its status
MarburgGermanyUnknown status
Krankenhaus der Barmherzigen Brüder - Herzzentrum Trier
Coordinator of this site? Confirm its status
TrierGermanyUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.